mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced  
Phone 01494 818 000
Current Jobs

HCP Representative
Location: London

Territory Manager - Sports Medicine
Location: Devon and Cornwall

Urology Sales Specialist
Location: West Midlands

Senior Brand Manager (Maternity Cover)
Location: Cambridge

Sales Specialist
Location: London

Global Planning Partner
Location: London

Skin Health Sales Representative
Location: Peterborough, Cambs, Northants

Territory Manager - Sports Medicine
Location: Western Ireland

Senior Business Unit Manager
Location: Berkshire

Senior Account Executive
Location: Kent

HCP Representative
Location: Scotland

Nurse Advisor
Location: Scottish Highlands

Nurse Advisor
Location: Forth Valley

Sales Specialist - PAS
Location: South East

Account Executive - AHS
Location: Midlands C04

Magic heart pill could drain health resources

Posted on 15/02/2006 in Industry related health news

Treating as many people as possible with the new polypill would not be cost effective, a study has claimed.

Polypill - which combines aspirin, a statin, three blood pressure-lowering agents and folic acid - could slash the risk of coronary artery disease and stroke, but health experts have said giving it to everyone at risk from the diseases would be too much of a drain on resources.

The team, led by Professor Oscar H Franco, said the so-called 'magic bullet' would need to be carefully targeted and cheap to manufacture for it to be a feasible option for people at risk from heart disease and stroke.

The pill has still to be fully tested, but in theory it has the potential to cut the risk of coronary artery disease by 88 per cent and stroke by 80 per cent in those between 55 and 64 years old.

Researchers from Erasmus University in Holland also found it had the potential to reduce heart attack deaths.

However, they said it should be targeted at over 60s or those at a high risk from heart disease to make it more cost effective.

Giving it to everyone over 60 would prevent up to 179 heart attacks and 33 strokes per 1,000 people, according to the research team's theoretical evidence.

The data was taken from more than 5,000 people between the ages of 28 and 62 who were monitored as part of the US Farmingham Heart study.

The team, who reported their findings in the Journal of Epidemiology and Community Health, wrote: "The polypill seems to potentially offer a highly effective intervention, but potential producers should be aware of the market limitations. The polypill may be the preventative method with potentially the greatest impact on public health in the western world, but is everything that glitters gold?

"Even when it is, it should certainly he a lot less expensive than gold to ensure a serious impact on the primary prevention of cardiovascular disease."


track© Adfero Ltd

Other news stories from 15/02/2006

Read more in the Zenopa News Archive

How this news is generated

Morag Shea
Scotland Manager


Pharmaceutical Sales Jobs | Pharmaceutical Executive Jobs | Pharmaceutical Marketing Jobs | Medical Sales Jobs | Medical Devices Marketing Jobs | Medical Executive Jobs
Dental Sales Jobs | Veterinary Sales Jobs | Scientific Sales Jobs | Consumer Healthcare Sales Jobs | Consumer Healthcare Management Jobs | Medical Writing Jobs
Medical Writer Jobs | Healthcare PR Jobs | Animal Health Sales Jobs

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2012 Zenopa Ltd | terms & conditions of use